Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Centre Francois Baclesse

Status: Enrolling

Conditions: Endometrial Cancer

Treatments: Other: tumour and blood samples

Study type: Observational

Funder types: Other

Identifiers

NCT06603506

2024-A01206-41 (Other Identifier)

Details and patient eligibility

About

This study comprises 3 stages:

1. Collection of tumor and blood samples.
2. Creation of organoid models based on tumor samples.
3. Development of functional tests to predict clinical response to treatment.

Enrollment: 16 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient aged 18 years or more

• Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.

• Patient with localized endometrial cancer, presenting:

  • A high-grade endometrioid histological type and/or
  • P53 mutation and/or
  • a non-endometrioid histological type regardless of P53 status.

• Patient affiliated to a social security scheme

• Information and signature of informed consent prior to any specific study procedure

Exclusion criteria

• Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
• Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.

Trial design

16 participants in 1 patient group

tumour and blood collection

Description:

tumour and blood collection for realization ex vivo organoid models

Treatment:

Other: tumour and blood samples